Su, Jiayu
Reynier, Jean-Baptiste
Fu, Xi
Zhong, Guojie
Jiang, Jiahao
Escalante, Rydberg Supo
Wang, Yiping
Aparicio, Luis
Izar, Benjamin
Knowles, David A.
Rabadan, Raul
Funding for this research was provided by:
National Institutes of Health (R35CA253126)
National Cancer Institute (U01CA243073, R37CA258829, R21CA263381, U01CA261822)
Center for Integrated Cellular Analysis (RM1HG011014)
Article History
Received: 2 February 2023
Accepted: 4 December 2023
First Online: 18 December 2023
Declarations
:
: Not applicable.
: Not applicable.
: R. R. is the founder of GenoTwin and member of the Scientific Advisory Board of Diatech Pharmacogenetics and Flahy. B. I. is a consultant for or received honoraria from Volastra Therapeutics, Johnson & Johnson/Janssen, Novartis, Eisai, AstraZeneca and Merck, and has received research funding to Columbia University from Agenus, Alkermes, Arcus Biosciences, Checkmate Pharmaceuticals, Compugen, Immunocore, Regeneron, and Synthekine. None of these activities is related to the results in the current manuscript.